NAT10 and posterior cortical atrophy: Clinical characterization results suggest a robust association between NAT10 and PCa drug resistance and recurrence, further corroborated by existing studies [33, 34], offering new insights into the potential of NAT10-mediated ac4C acetylation as a therapeutic target for overcoming resistance to androgen deprivation therapy in PCa.